CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

It uses CRISPR/Cas9 to make a patient’s haematopoietic stem cells produce high levels of foetal haemoglobin (HbF) in red blood cells, by introducing a gene known as BCL11A which down-regulates ...

HBF’s legal action against the developers behind Kings Square, including Cimic Group and companies linked to Seven Network, continues in the state’s highest court. Cimic and the other entities denied ...

Produced by the AI systems at Stock Traders Daily, this report offers a technical analysis of Harvest Brand Leaders Plus Income ETF (TSX: HBF). Our AI, honed over 20 years, identifies prime trading ...

Ms Fraser was replaced by former Deloitte director and HBF Health CFO Donna Carrington in July 2024. In October 2024, Andrew and Nicola Forrest revealed they would hand over the reins as Minderoo ...

To mark New Homes Week (3rd- 9th February) and its theme of Communities, Close Brothers Property Finance and the Home Builders Federation (HBF) have released a video series highlighting the vital role ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy ...